ArticleBosnian journal of basic medical sciences2020
The potential of metabolic and lipid profiling in inflammatory bowel diseases: A pilot study.
Article in Bosnian journal of basic medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Decline in Serum Lysophosphatidylcholine Species in Patients with Severe Inflammatory Bowel Disease.Journal of clinical medicine · 2025Article
- Elevated long-to-very-long-chain ceramide ratio correlates with disease severity in inflammatory bowel disease and primary sclerosing cholangitis.Scientific reports · 2025Article
- FECAL CALPROTECTIN AND INTESTINAL METABOLITES: WHAT IS THEIR IMPORTANCE IN THE ACTIVITY AND DIFFERENTIATION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES?Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2025Article
- Low-Density Lipoprotein and High-Density Lipoprotein as Biomarkers for Inflammatory Bowel Disease Activity Assessment.International journal of general medicine · 2025Article
- The Role of Host Genetics and Intestinal Microbiota and Metabolome as a New Insight into IBD Pathogenesis.International journal of molecular sciences · 2024Review
- Explainable AI-prioritized plasma and fecal metabolites in inflammatory bowel disease and their dietary associations.iScience · 2024Article
- Article
- Integrative Lipid Pseudotargeted Metabolomics and Amino Acids Targeted Metabolomics Unravel the Therapeutic Mechanism of Rhizoma Paridis Saponins on Experimental Colitis of Damp-Heat Type.Drug design, development and therapy · 2024Article
- Are We Ready to Reclassify Crohn's Disease Using Molecular Classification?Journal of clinical medicine · 2023Article
- Cassane diterpenoid ameliorates dextran sulfate sodium-induced experimental colitis by regulating gut microbiota and suppressing tryptophan metabolism.Frontiers in immunology · 2022Article
- The effect of tuina on ulcerative colitis model mice analyzed by gut microbiota and proteomics.Frontiers in microbiology · 2022Article
- Exploring the Phosphatidylcholine in Inflammatory Bowel Disease: Potential Mechanisms and Therapeutic Interventions.Current pharmaceutical design · 2022Review
- Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives.Computational and structural biotechnology journal · 2022Review
- Inflammatory Bowel Disease and COVID-19: How Microbiomics and Metabolomics Depict Two Sides of the Same Coin.Frontiers in microbiology · 2022Review
- Metabolomics Insights into Inflammatory Bowel Disease: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Systematic Review of Recent Lipidomics Approaches Toward Inflammatory Bowel Disease.Biomolecules & therapeutics · 2021Review
- MiMeNet: Exploring microbiome-metabolome relationships using neural networks.PLoS computational biology · 2021Article
- Analysis of Intestinal Microflora and Metabolites From Mice With DSS-Induced IBD Treated WithFrontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBDs) are conditions that still pose significant problems. A third of the patients are either misdiagnosed or a proper diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) cannot be made. We need new biomarkers, so that we can offer patients the best treatment and keep the disease in an inactive state for as long as possible. Alterations in metabolic profiles have been incriminated in the pathophysiology of IBD. The aim of the present study was to identify molecules that could serve as biomarkers for a positive diagnosis of IBD as well as to discriminate UC from colonic CD. Twenty-two patients with active colonic IBD (UC = 17, CD = 5) and 24 age- and gender-matched healthy controls were enrolled. Plasma lipid and metabolic profiles were quantified using ultra-high-performance liquid chromatography combined with mass spectrometry. Univariate and multivariate statistical tests were employed. Six lipid species and 7 metabolites were significantly altered in IBD patients compared to healthy controls, with the majority belonging to glycerophospholipid, linoleic acid, and sphingolipid metabolisms. Five lipid species and only 1 metabolite were significantly increased in UC compared to CD. This preliminary study suggests that lipid and metabolic profiling of serum can become diagnostic tools for IBD. In addition, they can be used to differentiate between CD and UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.